Hybrid SPPS-LPPS Is Becoming a Preferred Route for Long Peptides. Here’s Why

Guest Contribution – Hybrid SPPS-LPPS routes are gaining ground as therapeutic peptides grow longer. For shorter sequences, linear SPPS still works well, adding one amino acid at a time on resin. Past roughly 30 to 40 amino acids, that one-step-at-a-time approach starts to strain at a commercial scale. Each added step makes the chain harder to build cleanly, and the finished product costlier to purify. 

Hybrid routes ease this pressure by building the sequence in short pieces on resin. Those pieces are then joined in solution, spreading the difficulty across smaller, easier-to-control stages. As longer sequences move toward large-volume supply, more manufacturers are building this approach into their development plans.

Why Does Linear SPPS Struggle as Long Peptides Grow?

Linear SPPS struggles with long peptides because small losses at each step compound over dozens of steps. The growing chain also becomes harder to extend as it lengthens, which adds to those losses.

The first problem comes down to yield math. No coupling step reaches 100% completion, so a small share of chains misses out each time. Even at 99% per step, only about two-thirds of chains are complete after 40 couplings. At 60 couplings, that share falls to just over half.

The second problem makes this math worse. 

As chains get longer, they can fold back on themselves or stick to neighboring chains on the resin. These clumps hide the end of the chain, so the next amino acid attaches less reliably. Coupling efficiency can then slip below 99%, leaving even more incomplete chains behind.

All of these incomplete chains stay in the batch and must be removed during purification. The hardest ones are missing just one amino acid, so they look almost identical to the target. Separating them takes long, solvent-heavy purification runs, that cut the final yield further.

Every amino acid also goes onto the same chain, so the whole batch succeeds or fails together. A failure late in the sequence can undo weeks of earlier work. Together, these limits explain why manufacturers are splitting longer sequences into smaller, separately built pieces.

How Does a Hybrid SPPS-LPPS Route Work for Long Peptides?

A hybrid route breaks the target sequence into shorter fragments, usually three to five. Each fragment is built by SPPS, and the finished fragments are then joined in solution.

The process starts with deciding where to split the sequence. This is one of the earliest decisions in peptide process development, because split points shape the steps that follow. They set how well each fragment dissolves and how cleanly it joins the next one. They also influence a common side reaction at the join. 

During this reaction, the joining amino acid can flip into its mirror-image form. That flip creates an impurity that is hard to remove later. To limit it, teams often end fragments on glycine or proline. Glycine has no mirror-image form, and proline strongly resists the change.

With the split points set, each fragment is kept short enough for SPPS to run cleanly. When the fragments come off the resin, protective groups stay on their reactive side chains. These groups keep the side chains from reacting while the fragments are joined.

The joins themselves can run in standard batch reactors or in continuous flow systems. Flow offers tighter control over mixing and reaction time at each join. Once the last join is complete, the protective groups come o,ff and the full chain is purified.

For long peptides, the result is a set of shorter builds that are each easier to control than one continuous run.

Why Does Hybrid Synthesis Produce Cleaner Long Peptides?

Hybrid synthesis produces cleaner long peptides because impurities are caught and removed fragment by fragment. By the time the full chain is assembled, much of the clean-up is already done. Here are the three ways a hybrid route keeps impurities under control:

Each Fragment Is Purified Before Assembly

A short fragment is far easier to purify than a full-length chain. In a 10-residue fragment, a missing amino acid changes the size noticeably. That makes the flawed copy easier to separate from the correct one. Only fragments that meet their specification move on to be joined.

Failed Joins Leave Easy-to-Spot Impurities

When a join fails, the leftover fragment is much shorter than the full chain. That large size difference shows up clearly in routine testing and separates easily during purification. As a result, the hardest impurities to remove become less common in the final product.

Failures Stay Contained

Fragment-based building also reduces the batch risk that linear routes carry. A problem in one fragment batch affects only that fragment. It can be remade without discarding the other fragments or the work already done. For costly peptide batches, this protects both material and delivery schedules.

How Does Hybrid Synthesis Help Long Peptides Scale With Less Waste?

Hybrid synthesis helps scale long peptides because fragments can be made simultaneously. It also uses far less solvent than an extended SPPS run. Here’s how you can understand it: 

Parallel Production Shortens Timelines

In a linear build, each amino acid waits for the one before it. A hybrid route lets separate reactors make different fragments side by side. The full chain is ready sooner, and a delay on one fragment leaves the others on track.

Solvent and Waste Burden Drops

Much of the waste in SPPS comes from washing the resin after every step. An ACS Green Chemistry Institute article on peptide manufacturing puts the process mass intensity of SPPS at about 13,000. That means roughly 13,000 kilograms of materials go in for each kilogram of peptide produced. The same article notes that hybrid processes can substantially reduce this figure for longer GLP-1-class peptides.

Hybrid Routes Fit Large-Volume Demand

GLP-1-class peptides show that supply now depends on large-scale production. The FDA declared the shortage of one leading GLP-1 medicine resolved in February 2025. That came after FDA confirmation that manufacturing capacity could meet projected demand. Volumes like these are where the time and waste savings of hybrid routes matter most.

When Does a Hybrid Route Make Sense for Long Peptides?

A hybrid route makes most sense for longer or hard-to-build sequences headed for large commercial volumes. For short peptides produced in small quantities, linear SPPS is usually simpler and faster. Many sequences sit between these two cases, so the decision depends on a few specifics:

• Sequence length: Chains past roughly 30 amino acids, especially those prone to clumping, gain the most from splitting.
• Expected commercial volume: The extra development work pays off most at multi-kilogram scale and above.
• Fragment solubility: Some fragments dissolve poorly, which limits where the sequence can be split.
• Timing: Changing routes after regulatory filings means extra comparability work and new submissions.

The hybrid route does ask more of the development team. Each fragment requires its own purification and testing methods, and each joint needs its own controls. That upfront effort is the main reason short, low-volume peptides often stay on linear SPPS. For longer sequences headed to scale, the gains in purity and throughput often justify it.

FAQs

1. Can peptides with added side chains be made using a hybrid route?

Yes, peptides with added side chains, such as fatty-acid chains, often suit a hybrid route well. The side chain can be attached to one fragment before the joins. This keeps the more complex chemistry within one small piece. Only that fragment then needs the extra steps and checks for the side chain.

2. Can different fragments be made at different sites?

Yes, fragments can be made at different sites, as long as each one meets an agreed specification. This gives manufacturers more supply options. For example:

• A second site can be qualified to make a fragment if one site faces delays.
• Fragment supply can be split across regions to reduce reliance on one location.

3. How do manufacturers confirm the final peptide is correct?

Manufacturers confirm the final peptide with a set of standard tests after purification. The main checks include:

• Mass analysis to confirm the chain is the right size
• Purity testing to measure any remaining impurities
• Chiral testing to confirm no amino acids flipped at the joins

Together, these show the joins worked as planned.

4. Does a hybrid route need special equipment?

No, a hybrid route does not usually need special equipment. It uses SPPS reactors to build the fragments and standard reactors to join them in solution. What matters more is having both set-ups available at scale, with teams experienced in each method. This is why some companies work with a partner that runs both.

________________________________________________________________________________________________________________
Advertisements placed in our Guest Contribution sections are in no way intended as endorsements of the advertised products, services, or related advertiser claims by NewsroomPanama.com, the website’s owners, affiliated societies, or the editors. Read more here.